Research in innovative therapeutics aims to identify new, economically sustainable therapeutic approaches that can deliver better outcomes for patients and the community.
From 2001 to 2014, health care expenditure in Australia doubled to $140 billion (9.5% GDP), and has since been increasing at a rate of 7.7% per annum. The various tiers of government fund 68% of these costs, 11.5% of which can be attributed to pharmaceuticals alone.
The development of new and cost-effective therapeutics is critical for sustaining and advancing the delivery of health care to the Australian community. Our research aims to produce novel therapeutic approaches to enhance efficacy and specificity; lower the side effects; provide greater safety; and reduced need for hospitalisation or other health services.
Researchers across the faculty are focused on:
- identifying novel targets for therapy to prevent metastasis and modulate the progression of cancers
- identifying new biomarkers to identify disease, predict disease trajectories and monitor response to treatment
- developing tissue regeneration technologies to address tissue injuries and disease
- developing cost-effective in vitro models to replace animal models for testing therapeutic efficacy
- developing rigorous clinical evaluation approaches of novel combinations of existing therapeutic agents, including development of novel modes of delivery.
Our research centres and institutes working in this area
- Dame Roma Mitchell Cancer Research Laboratories (Professor Wayne Tilley)
- Freemasons Foundation Centre for Men’s Health (Professor Gary Wittert)
- Robinson Research Institute (Professor Sarah Robertson)
Our research groups working in this area
- Aquaporin Physiology and Drug Discovery (Professor Andrea Yool)
- Bone and Joint Research Laboratories (Professor David Haynes)
- Breast Cancer Research Unit (Professor Andreas Evdokiou)
- Gastrointestinal Neuro-Immune Interactions Group (Dr Patrick Hughes)
- Genome Editing Laboratory (Professor Paul Thomas)
- Hopwood Centre for Neurobiology (Professor Christopher Proud)
- Mesenchymal Stem Cell Group (Professor Stan Gronthos)
- Myeloma Research Laboratory (Professor Andrew Zannettino)
- Neuroimmunopharmacology Laboratory (Professor Mark Hutchinson)
- Otolaryngology, Head and Neck Surgery Group (Professor Peter-John Wormald)
- Ovarian and Reproductive Cancer Cell Biology (Professor Darryl Russell)
- Prostate Cancer Research Group (Professor Lisa Butler)
- Psychosis Research Group (Professor Cherrie Galletly)
- Reproductive Cancer Group (Dr Carmela Ricciardelli)
- Translational Neuropathology Laboratory (Associate Professor Renee Turner)
- Translational Vascular Function Research Collaborative (Professor John Beltrame)
For additional leads in this area of research, please contact Innovative Therapeutics researchers.
We offer exciting opportunities for researchers at the honours, masters and PhD levels. Our research degrees are open to a broad range of backgrounds, and range from basic sciences to clinical research. If you are interested in human health, consider furthering your research career with us.